Emerging immunotherapies and targeted therapies take aim at recently identified biomarkers ...

Immunotherapy, targeted treatments, HIPEC, and new delivery options ...

The FDA granted breakthrough status to Cogent's GIST drug combo after a trial showed it cut disease progression or death risk ...

Proton pump inhibitors are among the most commonly prescribed medications worldwide, but concerns about a possible link to ...

Scotland has approved its first CLDN18.2-targeted therapy for advanced gastric and GEJ cancer, expanding options for patients ...

Fecal microbiota transplants (FMT) can dramatically improve cancer treatment, suggest two groundbreaking studies published in ...

Colorectal cancer is one of the most prevalent tumors and a leading cause of cancer-related mortality. Despite advances ...

Advanced gastroesophageal adenocarcinoma (GEA) with HER2 positivity has long presented significant treatment challenges, with ...

Recent findings suggest no significant overall survival difference for patients with locally advanced esophageal squamous cell carcinoma who had neoadjuvant vs adjuvant therapy.